Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1992 6
1993 5
1994 7
1995 12
1996 7
1997 4
1998 4
1999 7
2000 11
2001 17
2002 12
2003 24
2004 10
2005 24
2006 16
2007 14
2008 16
2009 20
2010 15
2011 21
2012 30
2013 27
2014 28
2015 27
2016 25
2017 23
2018 18
2019 24
2020 34
2021 28
2022 33
2023 55
2024 52
2025 45

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

612 results

Results by year

Filters applied: . Clear all
Page 1
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP; focuSSced investigators. Khanna D, et al. Among authors: kuwana m. Lancet Respir Med. 2020 Oct;8(10):963-974. doi: 10.1016/S2213-2600(20)30318-0. Epub 2020 Aug 28. Lancet Respir Med. 2020. PMID: 32866440 Clinical Trial.
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Distler O, et al. Among authors: kuwana m. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112379 Free article. Clinical Trial.
Defining anti-synthetase syndrome: a systematic literature review.
Zanframundo G, Faghihi-Kashani S, Scirè CA, Bonella F, Corte TJ, Doyle TJ, Fiorentino D, Gonzalez-Gay MA, Hudson M, Kuwana M, Lundberg IE, Mammen A, McHugh N, Miller FW, Monteccucco C, Oddis CV, Rojas-Serrano J, Schmidt J, Selva-O'Callaghan A, Werth VP, Sakellariou G, Aggarwal R, Cavagna L. Zanframundo G, et al. Among authors: kuwana m. Clin Exp Rheumatol. 2022 Feb;40(2):309-319. doi: 10.55563/clinexprheumatol/8xj0b9. Epub 2022 Feb 25. Clin Exp Rheumatol. 2022. PMID: 35225224 Free PMC article.
2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease.
Kondoh Y, Makino S, Ogura T, Suda T, Tomioka H, Amano H, Anraku M, Enomoto N, Fujii T, Fujisawa T, Gono T, Harigai M, Ichiyasu H, Inoue Y, Johkoh T, Kameda H, Kataoka K, Katsumata Y, Kawaguchi Y, Kawakami A, Kitamura H, Kitamura N, Koga T, Kurasawa K, Nakamura Y, Nakashima R, Nishioka Y, Nishiyama O, Okamoto M, Sakai F, Sakamoto S, Sato S, Shimizu T, Takayanagi N, Takei R, Takemura T, Takeuchi T, Toyoda Y, Yamada H, Yamakawa H, Yamano Y, Yamasaki Y, Kuwana M; joint committee of Japanese Respiratory Society and Japan College of Rheumatology. Kondoh Y, et al. Among authors: kuwana m. Respir Investig. 2021 Nov;59(6):709-740. doi: 10.1016/j.resinv.2021.04.011. Epub 2021 Oct 1. Respir Investig. 2021. PMID: 34602377
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, Denton CP, Distler JHW, Hoffmann-Vold AM, Khanna D, Mayes MD, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beaty E, Girard M, Stowasser S, Zoz D, Maher TM; SENSCIS trial investigators. Highland KB, et al. Among authors: kuwana m. Lancet Respir Med. 2021 Jan;9(1):96-106. doi: 10.1016/S2213-2600(20)30330-1. Lancet Respir Med. 2021. PMID: 33412120 Free article. Clinical Trial.
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.
Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, Matucci-Cerinic M, Mayes M, Medsger T Jr, Merkel PA, Pope JE, Seibold JR, Steen V, Stevens W, Denton CP. Khanna D, et al. Among authors: kuwana m. J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231. J Scleroderma Relat Disord. 2017. PMID: 28516167 Free PMC article.
An international perspective on the future of systemic sclerosis research.
Abraham DJ, Black CM, Denton CP, Distler JHW, Domsic R, Feghali-Bostwick C, Gourh P, Hinchcliff M, Kolling F 4th, Kuwana M, Lafyatis R, Landegren U, Mahoney JM, Martin J, Matucci-Cerinic M, McMahan ZH, Mora AL, Mouthon L, Rabinovitch M, Rojas M, Rubin K, Trojanowska M, Varga J, Whitfield ML, Gabrielli A, Krieg T. Abraham DJ, et al. Among authors: kuwana m. Nat Rev Rheumatol. 2025 Mar;21(3):174-187. doi: 10.1038/s41584-024-01217-2. Epub 2025 Feb 14. Nat Rev Rheumatol. 2025. PMID: 39953141 Review.
Identification and management of interstitial lung disease associated with systemic sclerosis (SSc-ILD), rheumatoid arthritis (RA-ILD), and polymyositis/dermatomyositis (PM/DM-ILD): development of expert consensus-based clinical algorithms.
Kondoh Y, Bando M, Kawahito Y, Sato S, Suda T, Kuwana M. Kondoh Y, et al. Among authors: kuwana m. Expert Rev Respir Med. 2024 Jun;18(6):447-456. doi: 10.1080/17476348.2024.2374910. Epub 2024 Jul 15. Expert Rev Respir Med. 2024. PMID: 38943279 Free article.
Interstitial lung disease and myositis.
Gono T, Kuwana M. Gono T, et al. Among authors: kuwana m. Curr Opin Rheumatol. 2024 Nov 1;36(6):466-472. doi: 10.1097/BOR.0000000000001037. Epub 2024 Aug 12. Curr Opin Rheumatol. 2024. PMID: 39132763 Review.
612 results